<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774237</url>
  </required_header>
  <id_info>
    <org_study_id>VT-001</org_study_id>
    <nct_id>NCT04774237</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia</brief_title>
  <official_title>A 3-Dose, Multicenter, Randomized, Double-Masked, Crossover Phase 2 Safety and Efficacy Study of BRIMOCHOL™ Topical Ophthalmic Solution vs. BRIMOCHOL™ F Topical Ophthalmic Solution vs. Monotherapy With Carbachol Topical Ophthalmic Solution in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Visus Therapeutics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Visus Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Efficacy Study of BRIMOCHOL™ vs. BRIMOCHOL™ F vs. Carbachol Monotherapy Topical&#xD;
      Ophthalmic Solutions in Subjects with Emmetropic Phakic and Pseudophakic Presbyopia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 3-Dose, Multicenter, Randomized, Double-Masked, Crossover Phase 2 Safety and Efficacy Study&#xD;
      of BRIMOCHOL™ Topical Ophthalmic Solution vs. BRIMOCHOL™ F Topical Ophthalmic Solution vs.&#xD;
      Monotherapy with Carbachol Topical Ophthalmic Solution in Subjects with Emmetropic Phakic and&#xD;
      Pseudophakic Presbyopia&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Actual">October 19, 2021</completion_date>
  <primary_completion_date type="Actual">October 19, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in near VA</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of subjects with 3-line gains in near VA at various time points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in distance VA</measure>
    <time_frame>From baseline through hour 9 at each study visit</time_frame>
    <description>Percentage of subjects with 1-line loss in distance VA at various time points</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>BRIMOCHOL™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single drop in each eye at a visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BRIMOCHOL™ F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single drop in each eye at a visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbachol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single drop in each eye at a visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BRIMOCHOL™</intervention_name>
    <description>A single drop in each eye at a visit.</description>
    <arm_group_label>BRIMOCHOL™</arm_group_label>
    <other_name>carbachol/brimonidine tartrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BRIMOCHOL™ F</intervention_name>
    <description>A single drop in each eye at a visit.</description>
    <arm_group_label>BRIMOCHOL™ F</arm_group_label>
    <other_name>carbachol/brimonidine tartrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbachol</intervention_name>
    <description>A single drop in each eye at a visit.</description>
    <arm_group_label>Carbachol</arm_group_label>
    <other_name>carbachol monotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female in good general health&#xD;
&#xD;
          -  Must have presbyopia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergic reaction to the study drug or any of its components&#xD;
&#xD;
          -  Any disease or medical condition that, in the opinion of the Investigator, would&#xD;
             prevent the subject from participating in the study or might confound study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Global Research Management, Inc.</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Eye Care, PA</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Carbachol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

